SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with a cyclin-dependent kinase 4/6 inhibitor and endocrine therapy. The study met both co-primary endpoints, showing a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations, compared with standard-of-care endocrine therapy plus everolimus.
Levi Garraway, chief medical officer and head of Global Product Development, said: 'We look forward to discussing these results with regulatory authorities with the goal of making this giredestrant-based regimen available to many people with advanced ER-positive breast cancer.'
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
